New combo pill could tame stubborn diabetes
NCT ID NCT06571591
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether adding pioglitazone to the standard two-drug therapy (metformin and empagliflozin) helps people with type 2 diabetes who still have high blood sugar. Over 600 adults took part in this Phase 3 trial. The main goal was to see if the extra drug lowers HbA1c (a measure of blood sugar control) more than a placebo.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pioglitazone
- What this could lead to
- If successful, adding pioglitazone could help people with type 2 diabetes achieve better blood sugar control when two other drugs are not enough.
- What could go wrong
- This is a completed Phase 3 trial, but results are not yet published. Pioglitazone has known risks like weight gain and fluid retention, and may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for T2DM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celltrion
Incheon, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New diabetes pill HRS9531 enters Mid-Stage trial – could it help control blood sugar?
- New diabetes drug HM15275 enters Mid-Stage trial
- Sleep and menopause may harm diabetic women's hearts, study warns
- Could this pill protect kidneys in diabetes?
- Talking to your phone could detect diabetes, study finds
- RNA technology takes on diabetes: first human trial of exenatide nanoparticle injection